Deletion and deletion/insertion mutations in the juxtamembrane domain of the FLT3 gene in adult acute myeloid leukemia  by Deeb, Kristin K. et al.
Case report
Deletion and deletion/insertion mutations in the juxtamembrane
domain of the FLT3 gene in adult acute myeloid leukemia
Kristin K. Deeb a, Matthew T. Smonskey a, HanChun DeFedericis a, George Deeb c,
Sheila N.J. Sait d, Meir Wetzler b, Eunice S. Wang b, Petr Starostik a,n
a Molecular Diagnostics Laboratory, Department of Pathology and Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, United States
b Leukemia Service, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, United States
c Department of Pathology and Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, United States
d Cytogenetics Laboratory, Department of Pathology and Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, United States
a r t i c l e i n f o
Article history:
Received 8 July 2013
Received in revised form
20 September 2013
Accepted 23 September 2013






Acute myeloid leukemia (AML)
a b s t r a c t
In contrast to FLT3 ITD mutations, in-frame deletions in the FLT3 gene have rarely been described in adult
acute leukemia. We report two cases of AML with uncommon in-frame mutations in the juxtamembrane
domain of the FLT3 gene: a 3-bp (c.1770_1774delCTACGinsGT; p.F590_V592delinsLF) deletion/insertion
and a 12-bp (c.1780_1791delTTCAGAGAATAT; p.F594_Y597del) deletion. We veriﬁed by sequencing that
the reading frame of the FLT3 gene was preserved and by cDNA analysis that the mRNA of the mutant
allele was expressed in both cases. Given the recent development of FLT3 inhibitors, our ﬁndings may be
of therapeutic value for AML patients harboring similar FLT3 mutations.
& 2013 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Mutations in the FLT3 gene have been described in about 25% of
acute myeloid leukemia (AML). They are somewhat more common
in acute promyelocytic leukemia (APL), and have been associated
with an increased risk of relapse, decreased disease-free survival,
decreased event-free survival, and decreased overall survival [1].
These mutations result in constitutive activation of the FLT3
protein and are of two types: internal tandem duplication (ITD)
mutations in exon 14 resulting from the duplication and tandem
insertion of a portion of the juxtamembrane (JM) domain of the
FLT3 gene and missense mutations in exon 20 which alter the
aspartic acid residue at position 835 (D835) within the kinase
domain of the FLT3 protein. In the case of ITD mutations, the
duplicated segment length ranges in size from 3 to several
hundred base pairs and is always in-frame and therefore expected
to produce a functional protein [2]. Rare deletion and deletion/
insertion mutations affecting the FLT3 juxtamembrane region have
been described in childhood acute lymphoblastic leukemia [3,4].
Here, we report two cases of deletion and deletion/insertion
mutations in the juxtamembrane domain of FLT3 in adult AML.
Proper identiﬁcation of these mutations may have prognostic and




A 47 year-old man presented with complaints of shortness of
breath, fatigue, and weakness over several days. He had WBC of
42.3109/L and hemoglobin of 4.8 g/dL. Bone marrow morphol-
ogy showed 95% cellularity with 83% blasts and the case was
classiﬁed as AML M0 with myelodysplasia-related changes based
on the detection of del(5q) by FISH, as the minimal differentiation
of the leukemic blasts made the assessment of multilineage
dysplasia rather difﬁcult. Molecular diagnostic studies detected
wild-type NPM1 gene and atypically mutated FLT3 gene. The
patient underwent induction with cytarabine and idarubicin-
based chemotherapy, but had evidence of primary refractory
FLT3 mutation-positive AML on bone marrow biopsy performed
14 days after initiation of therapy. He then received high-dose
cytarabine and mitoxantrone re-induction therapy. Repeat bone
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marrow evaluation upon count recovery revealed remission with
2% blasts and no evidence of FLT3 mutation. He subsequently
underwent allogeneic stem cell transplantation from his sister and
remained in remission for ﬁve years, after which the AML relapsed
with a FLT3 D835 mutation and del(q5). He died shortly afterwards
of infectious complications following re-induction chemotherapy.
2.1.2. Patient #2
A 54 year-old man with a prior medical history of coronary artery
disease, diabetes, hypercholesterolemia, and hyperlipidemia presented
with new onset of widespread bruising and blood in stool. Physical
exam demonstrated scattered ecchymoses. Blood work revealed WBC
of 8.6109/L, hemoglobin of 9.8 g/L, and platelet count of 26109/L.
Prothrombin time was slightly elevated at 15.6 s (INR 1.25) with
normal activated partial thromboplastin and a reduced ﬁbrinogen
level of 163 mg/dL. Hematopathologic evaluation of blood and bone
marrow conﬁrmed the diagnosis of acute promyelocytic leukemia
(APL) with 91% marrow blasts/abnormal promyelocytes. Cytogenetics
revealed a reciprocal translocation between the long arms of chromo-
somes 15 and 17 in 19/20 cells, t(15;17)(q24;q21). Molecular studies
demonstrated a high level of the PMLRARalpha t(15;17) fusion
transcript (164% of control) by quantitative RT-PCR. An atypical FLT3
mutation was also identiﬁed. The patient was initiated on differentia-
tion therapy with oral retinoic acid (ATRA) 45 mg/m2 and arsenic
trioxide 0.15 mg/kg intravenously daily as previously described [5].
Pseudotumor cerebri, scrotal ulcerations, and persistent head-
aches necessitated ATRA dose reduction. The patient was sub-
sequently found to have CNS involvement by APL and received
multiple intrathecal methotrexate injections. He was discharged
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Fig. 1. Deletions in the juxtamembrane domain of the FLT3 gene. (A) FLT3 ITD fragment analysis showing wild-type peak (330 bp), and smaller PCR ampliﬁcation products
(327 bp and 318 bp) which correspond to a 3-bp deletion in patient #1 and a 12-bp deletion in patient #2, respectively. (B) Results of Sanger sequencing conﬁrming the
deletions. The wild-type (WT) FLT3 sequence is in lowercase. The sequence of the deletion is boxed. The deletion mutation starting point is depicted by ▲(red) in the
respective read directions, and the insertion is indicated by a blue underline. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the
web version of this article.)
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2.2. FLT3 ITD and D835 mutation fragment analysis
DNA was extracted from blood or bone marrow samples using
the EZ1 DNA Blood Kit (Qiagen, Germantown, MD) on the
BioRobot EZ1 system (Qiagen). The FLT3 PCR-based fragment
analysis assay was performed as previously described [6].
2.3. FLT3 juxtamembrane domain Sanger sequencing
Mutations detected in the juxtamembrane domain of the FLT3
gene underwent Sanger sequencing in both forward and reverse
directions with the Big Dye Terminator v 3.1 Cycle Sequencing Kit
(Life Technologies, Carlsbad, CA). Results were analyzed in Sequen-
cing Analysis v5.2 software (Life Technologies) and Lasergene
SeqMan Pro v10.0 (DNAStar, Madison, WI), and aligned to the
FLT3 reference gene (NCBI RefSeq NM_004119.2).
2.4. FLT3 mRNA analysis
RNA was extracted from patient samples using the miRNeasy
Mini Kit (Qiagen) and converted to cDNA with the RevertAid
First Strand cDNA Synthesis Kit (Thermo Scientiﬁc, Pittsburgh,
PA), which was subsequently ampliﬁed with primers FLT3F:
50-6-FAM-GCCAGCTACAGATGGTACAGG-30 and FLT3R: 50-TTGC-
GTTCATCACTTTTCCA-30. PCR products were analyzed on the ABI
3130xl Genetic Analyzer instrument (Life Technologies).
3. Results and discussion
Upon FLT3 ITD fragment analysis during routine molecular
diagnostics work-up at presentation, both patient samples showed
an unusual peak in the electropherogram (Fig. 1A). Besides the
wild-type allele of 330 bp, a shorter PCR product in the same
reaction pointed to the presence of a mutated allele showing a
deletion in the PCR-ampliﬁed juxtamembrane domain region.
Fragments shorter by 3-bp (327-bp) in patient #1 with a mutant
allele/wild-type FLT3 ratio of 0.29, and by 12-bp (318-bp) in
patient #2 with a ratio of 0.49 were detected. These fragments
were further analyzed by Sanger sequencing to elucidate the
nature of the deletions. Compared to the wild-type FLT3 sequence,
patient #1 had a 5-bp deletion (CTACG) mutation combined with a
2-bp (GT) insertion: c.1770_1774delCTACGinsGT mutation (Fig. 1B),
giving an overall 3 bp deletion as detected by FLT3 fragment
Fig. 2. FLT3 mutant allele expression. RT-PCR across the FLT3 juxtamembrane domain containing the deletions shows that all samples (HL60 serves as WT control) express
the wild-type allele (162 bp). In addition to that, the patient samples express the mutant alleles (del159 and del150, respectively).
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analysis. The deletion resulted in a p.F590_V592delinsLF amino
acid change in the juxtamembrane domain. Patient #2 had a
c.1780_1791delTTCAGAGAATAT (12-bp deletion) mutation (Fig. 1B)
resulting in p.F594_Y597del amino acid deletion in the juxtamem-
brane domain. Notably, these deletion and deletion/insertion muta-
tions were in-frame and the reading frame of the FLT3 gene was
preserved in both cases. Subsequently, the samples were tested for
mutant versus wild type allele expression using cDNA fragment
analysis. Both wild-type and mutant alleles were expressed at ratios
comparable to the results of the FLT3 ITD assay (Fig. 2).
FLT3 deletion and deletion/insertion mutations were previously
reported in cases of pediatric acute lymphoblastic leukemia [3,4],
but seldom described in adult acute leukemia. While the biological
signiﬁcance of this type of FLT3 mutations is unknown in human
disease, a small 10-amino acid (Tyr589 to Tyr599) deletion in the
juxtamembrane domain of FLT3 has been previously shown to lead
to constitutive activation of the FLT3 protein in transformed
murine IL3-dependent myeloid progenitor 32D cell line [7].
Similar deletion mutations are found in receptor tyrosine kinase
KIT in gastrointestinal stromal tumors (GIST) [8,9]. An in-frame
deletion of 7-amino acids in the juxtamembrane domain of
the KIT gene resulted in receptor autophosphorylation and malig-
nant transformation of mast cells [10]. These studies and our
ﬁndings that both patients showed in-frame deletions with mRNA
expressed (unfortunately, the samples did not yield enough
material for a Western blot) suggest that deletion and deletion/
insertion mutations in FLT3 juxtamembrane domain may lead to
receptor activation. Animal models would be a way to prove this
hypothesis and show, if inhibition of FLT3 can be therapeutically
exploited in such cases. Whether the presence of these mutations
in adult acute leukemia has prognostic signiﬁcance warrants
further investigation of a larger patient cohort.
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